Your Good Partner in Biology Research

CTRAM:I類限制性T細(xì)胞相關(guān)分子,免疫球蛋白超家族(Ig-SF)新成員!

日期:2023-12-07 10:44:34

CRTAM是一種新鑒定的免疫球蛋白超家族(Ig-SF)新成員。Ig-SF蛋白家族包含多個(gè)免疫調(diào)節(jié)和細(xì)胞粘附分子,這些蛋白在免疫系統(tǒng)的形成、應(yīng)答和細(xì)胞交互中扮演重要角色。CRTAM作為一種細(xì)胞表面跨膜蛋白,目前針對(duì)這一靶點(diǎn)的研究報(bào)道較少。相關(guān)研究表明CRTAM(CD355)與多種疾病關(guān)聯(lián),包括炎癥、哮喘、惡性間皮瘤和某些腫瘤疾病。CRTAM促進(jìn)促炎細(xì)胞因子的產(chǎn)生,可能參與自身免疫性疾病的免疫病理學(xué)。此外,CRTAM在免疫過程中對(duì)NK細(xì)胞殺傷腫瘤細(xì)胞起到關(guān)鍵作用,呈現(xiàn)出潛在的腫瘤靶向策略。今天,我們一起了解下這個(gè)Ig-SF新成員CRTAM!


1. 什么是CTRAM?

1.1 CTRAM的結(jié)構(gòu)

CRTAM(Class I-restricted T cell-associated molecule,又稱CD355)是I類限制性T細(xì)胞相關(guān)分子。CRTAM最初被發(fā)現(xiàn)在活化的CD8+T細(xì)胞和NKT細(xì)胞中表達(dá)較高,這些細(xì)胞受I類主要組織相容性復(fù)合物(MHC)的限制,CRTAM因此得名。人的CRTAM全長(zhǎng)有393個(gè)氨基酸,它的胞外區(qū)有兩個(gè)免疫球蛋白結(jié)構(gòu)域,第一個(gè)是IgV,第二是IgC。CRTAM胞內(nèi)有類-I PDZ(ESIV)結(jié)合基序,能連接到支架蛋白的PDZ區(qū)域。CRTAM的兩個(gè)Ig樣結(jié)構(gòu)域使其被歸類免疫球蛋白超家族(Ig-SF)的一個(gè)新成員。另有報(bào)道CRTAM還與Necl蛋白家族有關(guān),其氨基酸序列與Necl蛋白相似度約為20%。因此,研究者又將CRTAM歸類為Nectin樣家族的成員 [1-3]

1.2 CTRAM的表達(dá)和功能

CRTAM作為一種新鑒定的在T細(xì)胞激活標(biāo)記物,其在體外激活的iNKT、NK、CD8 T以及CD4 T細(xì)胞表面均表達(dá)。在小鼠中,CRTAM mRNA在脾臟、大腦和睪丸中可檢測(cè)到,在人體中則存在于脾臟、胸腺、腸道、淋巴結(jié)、肺、睪丸、卵巢和結(jié)腸中。研究發(fā)現(xiàn),CRTAM+CD4 T細(xì)胞產(chǎn)生的IFN-γ在DSS誘導(dǎo)的結(jié)腸炎小鼠模型中觀察到的炎癥過程中起到作用。在哮喘患者中檢測(cè)到CRTAM存在于CD4和CD8 T細(xì)胞、中性粒細(xì)胞以及嗜堿性粒細(xì)胞的細(xì)胞膜上。此外,經(jīng)抗原特異性刺激后,1型糖尿病患者的iNKT細(xì)胞中CRTAM表達(dá)與IFN-γ產(chǎn)生之間存在明顯關(guān)聯(lián)。這些發(fā)現(xiàn)提示,CRTAM表達(dá)細(xì)胞可能參與多種疾病相關(guān)的免疫病理學(xué)過程 [4-6]。

CRTAM的結(jié)構(gòu)

圖1. CRTAM的結(jié)構(gòu) [1]


2. CRTAM的配體是什么?

Nectin樣分子2(Necl-2)最近被確認(rèn)為CRTAM的結(jié)合伴侶。Necl-2有很多別名,包括TSLC1(tumor suppressor in lung cancer 1)、CADM1(cell adhesion molecule 1)、SynCAM1(synaptic cell adhesion molecule 1)、IgSF4(Immunoglobulin superfamily member 4)、RAI75。Necl-2屬于Nectin家族蛋白成員(Nectin1-4,Necl1-5)。Nectin和necl分子之間通過形成同源或異源的二聚體介導(dǎo)細(xì)胞黏附,他們也可以和免疫分子如DNAM-1(CD226),TIGIT,CD96,CRTAM等互相作用。多個(gè)研究通過細(xì)胞粘附實(shí)驗(yàn)、NK細(xì)胞與CD8細(xì)胞相關(guān)的功能實(shí)驗(yàn)鑒定出CRTAM的配體為Nectin家族蛋白Necl-2 [5, 7-8]。

研究發(fā)現(xiàn),CRTAM與其配體nectin-like 2(Necl2)的相互作用對(duì)小鼠CD4 T細(xì)胞產(chǎn)生IL-17、IL-22和IFN-γ的高效產(chǎn)生至關(guān)重要,并在CD8 T細(xì)胞和NK細(xì)胞的最佳細(xì)胞毒性中發(fā)揮作用。現(xiàn)有研究揭示,CRTAM與Necl-2的結(jié)合產(chǎn)生不同效應(yīng),具體取決于淋巴細(xì)胞類型。對(duì)于NK或CD8(+) T細(xì)胞,它促進(jìn)細(xì)胞毒性和IFNγ分泌,有利于免疫監(jiān)視。相反,CRTAM/Necl-2(TSLC1)相互作用會(huì)觸發(fā)激活的Vγ9Vδ2 γδ T細(xì)胞的細(xì)胞死亡,從而促進(jìn)腫瘤免疫逃逸(點(diǎn)擊查看以往CRTAM的配體:Necl-2/CADM1/TSLC1文章報(bào)道[5, 7-9]

CRTAM與Necl-2的結(jié)合產(chǎn)生不同效應(yīng)

圖2. CRTAM與Necl-2的結(jié)合產(chǎn)生不同效應(yīng) [9]


3. CRTAM相關(guān)的調(diào)控機(jī)制

越來越多的研究表明,CRTAM是一個(gè)多功能蛋白,在多種免疫過程中發(fā)揮作用。除了與Necl-2相互作用發(fā)揮免疫功能外,在小部分CD4 T細(xì)胞亞群中,CRTAM可與蛋白scrib相互作用,調(diào)節(jié)T細(xì)胞的極性,調(diào)節(jié)γ干擾素和IL-22的分泌 [10-12]。此外,Zeb1被發(fā)現(xiàn)是CRTAM的調(diào)控因子。Zeb1抑制CRTAM啟動(dòng)子活性,調(diào)控人T細(xì)胞中的CRTAM水平 [13]。當(dāng)CRTAM啟動(dòng)子中的特定元件突變時(shí),可消除Zeb1介導(dǎo)的轉(zhuǎn)錄抑制 [13]。然而,AP-1轉(zhuǎn)錄因子也被證明在人類T CD8淋巴細(xì)胞中調(diào)控CRTAM基因的表達(dá) [14]。目前CRTAM介導(dǎo)的信號(hào)轉(zhuǎn)導(dǎo)途徑尚不十分清楚,多數(shù)研究提示Necl-2和CRTAM相互作用對(duì)免疫過程至關(guān)重要。

研究顯示,CRTAM能增強(qiáng)NK細(xì)胞對(duì)腫瘤細(xì)胞的殺傷能力?;罨腘K細(xì)胞對(duì)轉(zhuǎn)染了Necl-2的腫瘤細(xì)胞的殺傷效果更顯著。體內(nèi)實(shí)驗(yàn)表明,使用轉(zhuǎn)染Necl-2的腫瘤細(xì)胞在裸鼠上進(jìn)行實(shí)驗(yàn)時(shí),裸鼠會(huì)迅速排斥腫瘤,預(yù)先清除裸鼠的NK細(xì)胞則明顯抑制了排斥作用。體外實(shí)驗(yàn)表明,Necl-2的腫瘤細(xì)胞活化CD8+T細(xì)胞時(shí),CRTAM表達(dá)增加,刺激后CD8+T細(xì)胞分泌γ干擾素。阻斷CRTAM-Necl-2互動(dòng)會(huì)抑制γ干擾素分泌。此外,Necl-2的抗原遞呈細(xì)胞可刺激CD8+T細(xì)胞分泌IL-22,參與皮膚細(xì)胞的免疫調(diào)節(jié)。CRTAM-Necl-2互動(dòng)調(diào)節(jié)CD8+T細(xì)胞淋巴結(jié)停留。CRTAM敲除小鼠對(duì)病毒免疫效果較弱,因其CD8+T細(xì)胞數(shù)量減少 [9-11]


4. CRTAM與疾病相關(guān)的研究

4.1 CRTAM與腸道菌群研究

研究發(fā)現(xiàn)CRTAM存在于腸道內(nèi)的T細(xì)胞中,參與調(diào)控T細(xì)胞在腸道的定位和維持,同時(shí)影響Th17細(xì)胞的分化和功能。CRTAM的缺失影響了腸道菌群的組成,在平衡狀態(tài)下,缺乏CRTAM的小鼠腸道中Firmicutes菌門的相對(duì)豐度增加,而Tenericutes菌門的相對(duì)豐度減少。研究使用野生型和缺乏CRTAM基因的小鼠,在感染或生理鹽水灌胃后觀察小鼠體重、糞便、腸道組織和腸道菌群的變化,以及血液和腸道淋巴結(jié)中Th17細(xì)胞的數(shù)量和功能。結(jié)果顯示,CRTAM促進(jìn)了感染后Th17細(xì)胞的增殖和分化,增強(qiáng)了小鼠對(duì)腸道寄生蟲的抵抗能力 [15]。

此外,CRTAM還維持了腸道菌群的平衡,防止了感染后菌群失調(diào)和炎癥反應(yīng)的發(fā)生。與此相反,CRTAM缺失的小鼠在感染后表現(xiàn)出更嚴(yán)重的體重下降、糞便稀釋、腸道損傷和菌群失調(diào),以及較低水平和功能的Th17細(xì)胞。因此,研究表明CRTAM是一種關(guān)鍵的免疫調(diào)節(jié)分子,其通過促進(jìn)Th17細(xì)胞的成熟發(fā)揮保護(hù)作用,預(yù)防小鼠在腸道寄生蟲感染中引起的菌群失調(diào)和炎癥反應(yīng),為未來腸道寄生蟲感染的治療提供了新的靶點(diǎn)和策略 [15]。

4.2 CRTAM與哮喘研究

研究發(fā)現(xiàn)過敏性哮喘患者的CD4+CRTAM+和CD8+CRTAM+T淋巴細(xì)胞以及CD177+CRTAM+中性粒細(xì)胞的百分比明顯增加,而IL5Rα+CRTAM+嗜酸性粒細(xì)胞的百分比無顯著差異。因此,該研究推測(cè)CRTAM在T細(xì)胞、嗜酸性粒細(xì)胞和中性粒細(xì)胞的表達(dá)可能與過敏性哮喘的支氣管炎癥相關(guān) [23]。另有研究指出維生素D水平與編碼CRTAM基因的變異在哮喘發(fā)作風(fēng)險(xiǎn)中有顯著的相互作用。在兩個(gè)兒童哮喘隊(duì)列(CAMP population和Costa Rican replication population)中進(jìn)行了全基因組互作分析,揭示了三個(gè)與CRTAM相關(guān)的常見變異,其中rs2272094是一種非同義多態(tài)性,其在維生素D水平較低時(shí)與哮喘發(fā)作率的增加相關(guān)。進(jìn)一步實(shí)驗(yàn)揭示了維生素D和rs2272094對(duì)CRTAM表達(dá)的影響。該研究結(jié)果在兩個(gè)獨(dú)立人群中得到了驗(yàn)證,揭示了維生素D與CRTAM調(diào)控的CD8+和自然殺傷性T細(xì)胞在哮喘發(fā)作中的重要作用 [16]。

4.3 CRTAM與糖尿病研究

CRTAM在活化的iNKT細(xì)胞、CD8+T細(xì)胞和少量CD4+T細(xì)胞表面得到表達(dá),并與小鼠CD4+T細(xì)胞的促炎癥表型相關(guān)。研究表明,受到α-半乳糖腦苷刺激的iNKT細(xì)胞可在18小時(shí)內(nèi)表達(dá)CRTAM,這表明iTCR與α-半乳糖腦苷的結(jié)合信號(hào)足以觸發(fā)CRTAM的表達(dá),而共刺激分子如CD40CD80CD86對(duì)CRTAM的表達(dá)并無影響。此外,研究人員還觀察到CRTAM的表達(dá)與健康人和I型糖尿病患者的iNKT細(xì)胞產(chǎn)生干擾素-γ(IFN-γ)的能力有明顯的關(guān)聯(lián)。這表明CRTAM可能在人類iNKT細(xì)胞產(chǎn)生IFN-γ的過程中扮演重要角色,同時(shí)可作為識(shí)別這些炎癥細(xì)胞的標(biāo)志之一 [17]

4.4 CRTAM與癌癥等疾病研究

在小鼠的肺癌模型中,研究者發(fā)現(xiàn)天花粉可通過調(diào)節(jié)腫瘤細(xì)胞中TSLC1和CRTAM的表達(dá)來發(fā)揮作用。進(jìn)一步的實(shí)驗(yàn)發(fā)現(xiàn),使用小干擾RNA(siRNA)阻斷TSLC1的表達(dá)可以顯著消除天花粉對(duì)效應(yīng)T細(xì)胞增殖和細(xì)胞因子分泌的影響。這表明天花粉通過促進(jìn)TSLC1和CRTAM之間的相互作用來增強(qiáng)抗腫瘤免疫應(yīng)答 [18];CRTAM在免疫調(diào)節(jié)型三陰性乳腺癌(TNBC)中也具有重要作用。CRTAM可增強(qiáng)免疫炎癥反應(yīng)并促進(jìn)CD8+T細(xì)胞的浸潤(rùn)。其次,CRTAM過表達(dá)能引發(fā)STAT1的磷酸化,并增加干擾素刺激基因的表達(dá) [19]。此外,也有報(bào)道提示CRTAM與急性淋巴性白血病 [20]、自身免疫脫發(fā) [21]、結(jié)核病 [22]關(guān)聯(lián)??傊?,這些研究表明,CRTAM參與調(diào)節(jié)免疫細(xì)胞的生物學(xué)行為和免疫應(yīng)答,有望成為多種疾病的免疫研究新的靶點(diǎn)。


5. CRTAM的臨床研究前景

HBM-1054作為當(dāng)前唯一針對(duì)CRTAM的臨床藥物,正在進(jìn)行臨床前的制劑開發(fā)和工藝優(yōu)化,預(yù)計(jì)將在2024年提交臨床試驗(yàn)申請(qǐng)。該藥物由和鉑醫(yī)藥(上海)有限責(zé)任公司開發(fā),其臨床適應(yīng)癥尚未公布,但可能涉及CTRAM高表達(dá)的腫瘤類型,比如肺癌、乳腺癌和胃癌等。當(dāng)前對(duì)于CRTAM的臨床藥物開發(fā)和評(píng)價(jià)仍相對(duì)不足。因此,HBM-1054的安全性和有效性需要更多的臨床數(shù)據(jù)來證實(shí)。隨著對(duì)CRTAM及其在腫瘤免疫治療中作用的深入研究,更多的創(chuàng)新和合作是必要的,這將有助于擴(kuò)大對(duì)CRTAM的理解,并為這一領(lǐng)域帶來更多新型研究策略。

為鼎力協(xié)助科研和藥企人員針對(duì)CTRAM在腸道、哮喘、糖尿病以及癌癥等疾病中的臨床應(yīng)用研究,CUSABIO推出CTRAM活性蛋白(CSB-MP005998HU2; CSB-MP614820MO),助力您在CTRAM機(jī)制方面的研究或其潛在臨床價(jià)值的探索。

華美 CUSABIO CTRAM 蛋白

Recombinant Human Cytotoxic and regulatory T-cell molecule (CRTAM), partial (Active) Code: CSB-MP005998HU2

High Purity Validated by SDS-PAGE
High Purity Validated by SDS-PAGE

The high purity was greater than 95% as determined by SDS-PAGE.

Excellent Bioactivity Validated by Functional ELISA
Excellent Bioactivity Validated by Functional ELISA

Immobilized Human CRTAM at 2μg/mL can bind Human CADM1(CSB-MP004425HUd9). The EC50 is 2.277-2.649 ng/mL.

Recombinant Mouse Cytotoxic and regulatory T-cell molecule (Crtam), partial (Active) Code: CSB-MP614820MO

High Purity Validated by SDS-PAGE
High Purity Validated by SDS-PAGE

The high purity was greater than 90% as determined by SDS-PAGE.

Excellent Bioactivity Validated by Functional ELISA
Excellent Bioactivity Validated by Functional ELISA

Immobilized Mouse Cadm1 (CSB-MP004425MO) at 2μg/mL can bind Mouse Crtam. The EC50 is 54.36 -61.77 ng/mL.


參考文獻(xiàn):

[1] Zhang Shuijun. Study on the molecular mechanism of interaction between NK cell receptors and Nectin/Necl family ligands [D]. China University of Science and Technology, 2014.

[2] Zhang, Shuijun, et al. "Competition of cell adhesion and immune recognition: Insights into the interaction between CRTAM and nectin-like 2." Structure 21.8 (2013): 1430-1439.

[3] Yeh, Jung-Hua, Sachdev S. Sidhu, and Andrew C. Chan. "Regulation of a late phase of T cell polarity and effector functions by Crtam." Cell 132.5 (2008): 846-859.

[4] Garay, Erika, et al. "CRTAM: A molecule involved in epithelial cell adhesion." Journal of cellular biochemistry 111.1 (2010): 111-122.

[5] Arase, Noriko, et al. "Heterotypic interaction of CRTAM with Necl2 induces cell adhesion on activated NK cells and CD8+ T cells." International immunology 17.9 (2005): 1227-1237.

[6] Galibert, Laurent, et al. "Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule*?." Journal of Biological Chemistry 280.23 (2005): 21955-21964.

[7] Boles, Kent S., et al. "The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM." Blood 106.3 (2005): 779-786.

[8] Dessarthe, Beno?t, et al. "CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells." The Journal of Immunology 190.9 (2013): 4868-4876.

[9] Nectins and nectin-like receptors DNAM-1 and CRTAM: New ways for tumor escape

[10] Leavy, Olive. "Polarity and CRTAM: a matter of timing." Nature Reviews Immunology 8.4 (2008): 246-246.

[11] Takeuchi, Arata, et al. "CRTAM determines the CD4+ cytotoxic T lymphocyte lineage." Journal of Experimental Medicine 213.1 (2016): 123-138.

[12] YEH, JUNG‐HUA, Sachdev S. Sidhu, and Andrew C. Chan. "Crtam regulates a late phase of T cell polarity and IFNγ/IL22 cytokine production." (2008): 384-384.

[13] Rojas-Marquez, C., et al. "CRTAM is negatively regulated by ZEB1 in T cells." Molecular Immunology 66.2 (2015): 290-298.

[14] Valle-Rios, Ricardo, et al. "Characterization of CRTAM gene promoter: AP-1 transcription factor control its expression in human T CD8 lymphocytes." Molecular immunology 46.16 (2009): 3379-3387.

[15] Perez-Lopez, Araceli, et al. "CRTAM shapes the gut microbiota and enhances the severity of infection." The Journal of Immunology 203.2 (2019): 532-543.

[16] Du, Rose, et al. "Genome-wide association study reveals class I MHC–restricted T cell–associated molecule gene (CRTAM) variants interact with vitamin D levels to affect asthma exacerbations." Journal of allergy and clinical immunology 129.2 (2012): 368-373.

[17] Beristain-Covarrubias, Nonantzin, et al. "Class I-restricted T cell-associated molecule is a marker for IFN-γ-producing iNKT cells in healthy subjects and patients with type 1 diabetes." Journal of Interferon & Cytokine Research 37.1 (2017): 39-49.

[18] Cai, Yuchan, et al. "Trichosanthin enhances anti-tumor immune response in a murine Lewis lung cancer model by boosting the interaction between TSLC1 and CRTAM." Cellular & molecular immunology 8.4 (2011): 359-367.

[19] Zheng, Shuyue, et al. "CRTAM promotes antitumor immune response in triple negative breast cancer by enhancing CD8+ T cell infiltration." (2023).

[20] Ramírez-Ramírez, Dalia, et al. "CRTAM+ NK cells endowed with suppressor properties arise in leukemic bone marrow." Journal of Leukocyte Biology 105.5 (2019): 999-1013.

[21] Giangreco, Adam, et al. "Epidermal Cadm1 expression promotes autoimmune alopecia via enhanced T cell adhesion and cytotoxicity." The Journal of Immunology 188.3 (2012): 1514-1522.

[22] Lai, Rachel PJ, et al. "Transcriptomic characterization of tuberculous sputum reveals a host Warburg effect and microbial cholesterol catabolism." Mbio 12.6 (2021): e01766-21.

[23] Ramirez-Velazquez, Carlos, et al. "Peripheral blood T cells and neutrophils from asthma patients express class-I MHC-restricted T cell-associated molecule." Allergy, Asthma & Clinical Immunology 10 (2014): 1-6.